In the crystal of the title compound, the molecules are linked by N—H⋯N hydrogen bonds, generating a C(4) chain extending along the c-axis direction.
Keywords: crystal structure, benzimidazole, hydrogen bonding
Abstract
In the crystal of the title compound, C12H17N3, the molecules are linked by N—H⋯N hydrogen bonds, generating a C(4) chain extending along the c-axis direction. One of the ethyl groups is disordered over two sets of sites with a refined occupancy ratio of 0.582 (15):0.418 (15).
Structure description
Benzimidazole and its derivatives show a wide range of pharmacological activities including antimicrobial, antifungal, antihistaminic, anti-inflammatory, antiviral, and antioxidant effects (e.g., Walia et al., 2011 ▸; Navarrete-Vazquez et al., 2001 ▸). The present research focuses on elucidating the hydrogen-bonding patterns exhibited by the title compound, C12H17N3.
The asymmetric unit is shown in Fig. 1 ▸. As expected, the benzimidazole (N2,N3,C6–C12) ring system is almost planar with a maximum deviation of 0.022 (8) Å for C6. The N2—C7—C8—N3 torsion angle is −155.9 (5)° and the C11/C12 ethyl group is disordered over two sets of sites with a refined occupancy ratio of 0.582 (15):0.418 (15). In the extended structure (Fig. 2 ▸), the molecules are connected by N1—H1⋯N2 hydrogen bonds (Table 1 ▸) to form C(4) chains propagating along the c-axis direction.
Figure 1.
The asymmetric unit of the title compound with displacement ellipsoids drawn at the 30% probability level.
Figure 2.
The crystal packing of the title compound.
Table 1. Hydrogen-bond geometry (Å, °).
| D—H⋯A | D—H | H⋯A | D⋯A | D—H⋯A |
|---|---|---|---|---|
| N1—H1⋯N2i | 0.86 | 2.06 | 2.873 (4) | 157 |
Symmetry code: (i)
.
There are thousands of benzimidazole derivatives in the Cambridge Structural Database (CSD; Version 5.43, update to November 2022; Groom et al., 2016 ▸) with three examples being methyl 2-[(1H-benzimidazol-2-ylmethyl)amino]benzoate (CSD refcode VARDEZ; Ghani et al., 2011 ▸), 1-(1H-benzimidazol-2-yl)-N,N-bis[(1H-benzimidazol-2-yl)methyl]methanamine methanol solvate (IHILIX; Anzaldo-Olivares et al., 2020 ▸) and 1-(1-methyl-1H-benzimidazol-2-yl)-N-[(1-methyl-1H-benzimidazol-2-yl)methyl]methanamine (TAZJIR; Gaoxiang et al., 2022 ▸).
Synthesis and crystallization
The title compound was prepared according to the literature method (Lingala et al., 2011). Single crystals were obtained by slowly evaporating a dichloromethane solution of the title compound.
Refinement
Crystal data, data collection and structure refinement details are summarized in Table 2 ▸.
Table 2. Experimental details.
| Crystal data | |
| Chemical formula | C12H17N3 |
| M r | 203.28 |
| Crystal system, space group | Orthorhombic, Pca21 |
| Temperature (K) | 293 |
| a, b, c (Å) | 7.9290 (7), 15.3027 (15), 10.0486 (6) |
| V (Å3) | 1219.25 (18) |
| Z | 4 |
| Radiation type | Mo Kα |
| μ (mm−1) | 0.07 |
| Crystal size (mm) | 0.36 × 0.33 × 0.30 |
| Data collection | |
| Diffractometer | Agilent Xcalibur, Atlas, Gemini |
| Absorption correction | Analytical (SADABS; Krause et al., 2015 ▸) |
| Tmin, Tmax | 0.507, 0.578 |
| No. of measured, independent and observed [I > 2σ(I)] reflections | 3304, 2135, 1138 |
| R int | 0.036 |
| (sin θ/λ)max (Å−1) | 0.675 |
| Refinement | |
| R[F2 > 2σ(F2)], wR(F2), S | 0.066, 0.130, 1.18 |
| No. of reflections | 2135 |
| No. of parameters | 158 |
| No. of restraints | 41 |
| H-atom treatment | H-atom parameters constrained |
| Δρmax, Δρmin (e Å−3) | 0.11, −0.10 |
| Absolute structure | Flack x determined using 249 quotients [(I+)−(I−)]/[(I+)+(I−)] (Parsons et al., 2013 ▸) |
| Absolute structure parameter | −1.1 (10) |
Supplementary Material
Crystal structure: contains datablock(s) global, I. DOI: 10.1107/S241431462401006X/hb4488sup1.cif
Structure factors: contains datablock(s) I. DOI: 10.1107/S241431462401006X/hb4488Isup2.hkl
Supporting information file. DOI: 10.1107/S241431462401006X/hb4488Isup3.cml
CCDC reference: 2376300
Additional supporting information: crystallographic information; 3D view; checkCIF report
full crystallographic data
(1H-Benzodiazol-2-ylmethyl)diethylamine . Crystal data
| C12H17N3 | Dx = 1.107 Mg m−3 |
| Mr = 203.28 | Mo Kα radiation, λ = 0.71073 Å |
| Orthorhombic, Pca21 | Cell parameters from 9307 reflections |
| a = 7.9290 (7) Å | θ = 3.5–26.4° |
| b = 15.3027 (15) Å | µ = 0.07 mm−1 |
| c = 10.0486 (6) Å | T = 293 K |
| V = 1219.25 (18) Å3 | Block, colouress |
| Z = 4 | 0.36 × 0.33 × 0.30 mm |
| F(000) = 440 |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Data collection
| Agilent Xcalibur, Atlas, Gemini diffractometer | 1138 reflections with I > 2σ(I) |
| Radiation source: fine-focus sealed tube | Rint = 0.036 |
| ω scans | θmax = 28.7°, θmin = 3.5° |
| Absorption correction: analytical (SADABS; Krause et al., 2015) | h = −10→8 |
| Tmin = 0.507, Tmax = 0.578 | k = −8→20 |
| 3304 measured reflections | l = −8→13 |
| 2135 independent reflections |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Refinement
| Refinement on F2 | Hydrogen site location: inferred from neighbouring sites |
| Least-squares matrix: full | H-atom parameters constrained |
| R[F2 > 2σ(F2)] = 0.066 | w = 1/[σ2(Fo2) + (0.0388P)2] where P = (Fo2 + 2Fc2)/3 |
| wR(F2) = 0.130 | (Δ/σ)max < 0.001 |
| S = 1.18 | Δρmax = 0.11 e Å−3 |
| 2135 reflections | Δρmin = −0.10 e Å−3 |
| 158 parameters | Absolute structure: Flack x determined using 249 quotients [(I+)-(I-)]/[(I+)+(I-)] (Parsons et al., 2013) |
| 41 restraints | Absolute structure parameter: −1.1 (10) |
| Primary atom site location: dual |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Special details
| Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. |
| Refinement. All the H atoms were positioned geometrically (C—H = 0.96–0.97 A°) and refined using a riding model with Uiso(H) = 1.2 Ueq(C) or 1.5 Ueq(methyl C). |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)
| x | y | z | Uiso*/Ueq | Occ. (<1) | |
| N1 | 0.2389 (4) | 0.3102 (2) | 0.0373 (3) | 0.0597 (10) | |
| H1 | 0.284732 | 0.301682 | 0.113816 | 0.072* | |
| N2 | 0.1987 (4) | 0.3027 (3) | −0.1813 (3) | 0.0659 (11) | |
| N3 | 0.5022 (5) | 0.1850 (4) | 0.0249 (4) | 0.0951 (15) | |
| C1 | 0.0952 (5) | 0.3570 (3) | 0.0120 (3) | 0.0515 (11) | |
| C2 | −0.0116 (6) | 0.4053 (3) | 0.0930 (4) | 0.0648 (13) | |
| H2 | 0.005609 | 0.408829 | 0.184357 | 0.078* | |
| C3 | −0.1425 (6) | 0.4474 (3) | 0.0331 (5) | 0.0761 (14) | |
| H3 | −0.216070 | 0.480461 | 0.084546 | 0.091* | |
| C4 | −0.1685 (6) | 0.4418 (3) | −0.1041 (4) | 0.0791 (15) | |
| H4 | −0.259316 | 0.471219 | −0.141747 | 0.095* | |
| C5 | −0.0640 (6) | 0.3942 (3) | −0.1845 (4) | 0.0739 (14) | |
| H5 | −0.083221 | 0.390253 | −0.275557 | 0.089* | |
| C6 | 0.0716 (5) | 0.3521 (3) | −0.1255 (3) | 0.0570 (13) | |
| C7 | 0.2952 (5) | 0.2799 (3) | −0.0819 (4) | 0.0643 (12) | |
| C8 | 0.4587 (6) | 0.2325 (4) | −0.0949 (4) | 0.0909 (17) | |
| H8A | 0.451582 | 0.191793 | −0.168709 | 0.109* | |
| H8B | 0.547429 | 0.274120 | −0.114689 | 0.109* | |
| C9 | 0.3974 (11) | 0.1078 (5) | 0.0413 (6) | 0.131 (2) | |
| H9A | 0.436683 | 0.062760 | −0.019218 | 0.158* | |
| H9B | 0.282447 | 0.122226 | 0.016695 | 0.158* | |
| C10 | 0.3979 (10) | 0.0716 (5) | 0.1815 (7) | 0.165 (3) | |
| H10A | 0.386626 | 0.118764 | 0.243885 | 0.248* | |
| H10B | 0.502133 | 0.041431 | 0.197381 | 0.248* | |
| H10C | 0.305414 | 0.031777 | 0.192073 | 0.248* | |
| C11A | 0.6923 (15) | 0.1942 (10) | 0.0568 (12) | 0.099 (5) | 0.582 (15) |
| H11A | 0.722510 | 0.255582 | 0.058529 | 0.118* | 0.582 (15) |
| H11B | 0.714977 | 0.169826 | 0.144064 | 0.118* | 0.582 (15) |
| C12A | 0.797 (2) | 0.1479 (12) | −0.0451 (15) | 0.136 (6) | 0.582 (15) |
| H12A | 0.756247 | 0.089389 | −0.056573 | 0.205* | 0.582 (15) |
| H12B | 0.912622 | 0.146040 | −0.015698 | 0.205* | 0.582 (15) |
| H12C | 0.790966 | 0.178585 | −0.128247 | 0.205* | 0.582 (15) |
| C11B | 0.6574 (15) | 0.1307 (12) | 0.0073 (17) | 0.096 (6) | 0.418 (15) |
| H11C | 0.664688 | 0.106808 | −0.081926 | 0.116* | 0.418 (15) |
| H11D | 0.662348 | 0.083481 | 0.071549 | 0.116* | 0.418 (15) |
| C12B | 0.793 (3) | 0.1976 (13) | 0.032 (3) | 0.121 (8) | 0.418 (15) |
| H12D | 0.789364 | 0.241313 | −0.036326 | 0.181* | 0.418 (15) |
| H12E | 0.901286 | 0.169560 | 0.031495 | 0.181* | 0.418 (15) |
| H12F | 0.774788 | 0.224638 | 0.117173 | 0.181* | 0.418 (15) |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Atomic displacement parameters (Å2)
| U11 | U22 | U33 | U12 | U13 | U23 | |
| N1 | 0.0612 (18) | 0.085 (3) | 0.0325 (16) | 0.003 (2) | −0.0023 (16) | −0.0003 (19) |
| N2 | 0.074 (2) | 0.093 (3) | 0.0311 (17) | 0.014 (2) | −0.0006 (17) | 0.0026 (19) |
| N3 | 0.078 (3) | 0.131 (4) | 0.076 (2) | 0.027 (3) | 0.008 (2) | 0.032 (3) |
| C1 | 0.057 (2) | 0.059 (3) | 0.039 (2) | −0.002 (2) | 0.0025 (18) | 0.004 (2) |
| C2 | 0.073 (3) | 0.074 (3) | 0.048 (2) | −0.001 (3) | 0.010 (2) | −0.003 (2) |
| C3 | 0.075 (3) | 0.078 (4) | 0.075 (3) | 0.010 (3) | 0.021 (3) | 0.003 (3) |
| C4 | 0.075 (3) | 0.093 (4) | 0.070 (3) | 0.017 (3) | −0.003 (2) | 0.020 (3) |
| C5 | 0.073 (3) | 0.093 (4) | 0.056 (3) | 0.001 (3) | −0.008 (2) | 0.008 (3) |
| C6 | 0.061 (3) | 0.071 (4) | 0.040 (2) | 0.000 (3) | 0.0020 (18) | 0.004 (2) |
| C7 | 0.067 (2) | 0.086 (3) | 0.040 (2) | 0.011 (2) | 0.0071 (19) | 0.001 (2) |
| C8 | 0.084 (3) | 0.136 (5) | 0.053 (3) | 0.039 (3) | 0.013 (2) | 0.012 (3) |
| C9 | 0.190 (7) | 0.100 (6) | 0.104 (5) | 0.027 (5) | 0.003 (5) | 0.005 (5) |
| C10 | 0.234 (9) | 0.131 (6) | 0.130 (6) | 0.009 (6) | 0.029 (6) | 0.039 (5) |
| C11A | 0.070 (8) | 0.105 (12) | 0.120 (10) | 0.009 (10) | −0.007 (7) | 0.007 (8) |
| C12A | 0.107 (11) | 0.139 (14) | 0.163 (14) | 0.027 (11) | 0.024 (11) | 0.012 (11) |
| C11B | 0.070 (9) | 0.121 (16) | 0.098 (10) | 0.006 (10) | 0.000 (8) | 0.014 (10) |
| C12B | 0.066 (11) | 0.121 (19) | 0.18 (2) | −0.007 (15) | −0.020 (16) | 0.022 (16) |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Geometric parameters (Å, º)
| N1—C7 | 1.360 (5) | C8—H8A | 0.9700 |
| N1—C1 | 1.369 (5) | C8—H8B | 0.9700 |
| N1—H1 | 0.8600 | C9—C10 | 1.513 (8) |
| N2—C7 | 1.306 (5) | C9—H9A | 0.9700 |
| N2—C6 | 1.379 (5) | C9—H9B | 0.9700 |
| N3—C8 | 1.448 (6) | C10—H10A | 0.9600 |
| N3—C9 | 1.453 (8) | C10—H10B | 0.9600 |
| N3—C11B | 1.496 (15) | C10—H10C | 0.9600 |
| N3—C11A | 1.547 (13) | C11A—C12A | 1.498 (10) |
| C1—C2 | 1.388 (5) | C11A—H11A | 0.9700 |
| C1—C6 | 1.396 (4) | C11A—H11B | 0.9700 |
| C2—C3 | 1.362 (6) | C12A—H12A | 0.9600 |
| C2—H2 | 0.9300 | C12A—H12B | 0.9600 |
| C3—C4 | 1.396 (6) | C12A—H12C | 0.9600 |
| C3—H3 | 0.9300 | C11B—C12B | 1.505 (11) |
| C4—C5 | 1.367 (6) | C11B—H11C | 0.9700 |
| C4—H4 | 0.9300 | C11B—H11D | 0.9700 |
| C5—C6 | 1.387 (5) | C12B—H12D | 0.9600 |
| C5—H5 | 0.9300 | C12B—H12E | 0.9600 |
| C7—C8 | 1.491 (6) | C12B—H12F | 0.9600 |
| C7—N1—C1 | 106.7 (3) | N3—C9—C10 | 113.6 (6) |
| C7—N1—H1 | 126.7 | N3—C9—H9A | 108.8 |
| C1—N1—H1 | 126.7 | C10—C9—H9A | 108.8 |
| C7—N2—C6 | 105.3 (3) | N3—C9—H9B | 108.8 |
| C8—N3—C9 | 111.5 (5) | C10—C9—H9B | 108.8 |
| C8—N3—C11B | 112.1 (7) | H9A—C9—H9B | 107.7 |
| C9—N3—C11B | 91.9 (7) | C9—C10—H10A | 109.5 |
| C8—N3—C11A | 111.0 (6) | C9—C10—H10B | 109.5 |
| C9—N3—C11A | 127.4 (7) | H10A—C10—H10B | 109.5 |
| N1—C1—C2 | 132.6 (4) | C9—C10—H10C | 109.5 |
| N1—C1—C6 | 105.6 (3) | H10A—C10—H10C | 109.5 |
| C2—C1—C6 | 121.8 (4) | H10B—C10—H10C | 109.5 |
| C3—C2—C1 | 117.2 (4) | C12A—C11A—N3 | 111.0 (13) |
| C3—C2—H2 | 121.4 | C12A—C11A—H11A | 109.4 |
| C1—C2—H2 | 121.4 | N3—C11A—H11A | 109.4 |
| C2—C3—C4 | 121.3 (4) | C12A—C11A—H11B | 109.4 |
| C2—C3—H3 | 119.3 | N3—C11A—H11B | 109.4 |
| C4—C3—H3 | 119.3 | H11A—C11A—H11B | 108.0 |
| C5—C4—C3 | 121.8 (5) | C11A—C12A—H12A | 109.5 |
| C5—C4—H4 | 119.1 | C11A—C12A—H12B | 109.5 |
| C3—C4—H4 | 119.1 | H12A—C12A—H12B | 109.5 |
| C4—C5—C6 | 117.7 (4) | C11A—C12A—H12C | 109.5 |
| C4—C5—H5 | 121.1 | H12A—C12A—H12C | 109.5 |
| C6—C5—H5 | 121.1 | H12B—C12A—H12C | 109.5 |
| N2—C6—C5 | 130.4 (3) | N3—C11B—C12B | 101.0 (16) |
| N2—C6—C1 | 109.5 (4) | N3—C11B—H11C | 111.6 |
| C5—C6—C1 | 120.2 (4) | C12B—C11B—H11C | 111.6 |
| N2—C7—N1 | 113.0 (3) | N3—C11B—H11D | 111.6 |
| N2—C7—C8 | 124.9 (3) | C12B—C11B—H11D | 111.6 |
| N1—C7—C8 | 121.9 (4) | H11C—C11B—H11D | 109.4 |
| N3—C8—C7 | 112.2 (3) | C11B—C12B—H12D | 109.5 |
| N3—C8—H8A | 109.2 | C11B—C12B—H12E | 109.5 |
| C7—C8—H8A | 109.2 | H12D—C12B—H12E | 109.5 |
| N3—C8—H8B | 109.2 | C11B—C12B—H12F | 109.5 |
| C7—C8—H8B | 109.2 | H12D—C12B—H12F | 109.5 |
| H8A—C8—H8B | 107.9 | H12E—C12B—H12F | 109.5 |
| C7—N1—C1—C2 | −176.9 (4) | C6—N2—C7—C8 | −174.1 (5) |
| C7—N1—C1—C6 | 0.1 (5) | C1—N1—C7—N2 | −0.6 (5) |
| N1—C1—C2—C3 | 177.3 (4) | C1—N1—C7—C8 | 174.5 (4) |
| C6—C1—C2—C3 | 0.7 (6) | C9—N3—C8—C7 | 73.2 (6) |
| C1—C2—C3—C4 | 0.2 (7) | C11B—N3—C8—C7 | 174.5 (8) |
| C2—C3—C4—C5 | −0.1 (8) | C11A—N3—C8—C7 | −138.7 (6) |
| C3—C4—C5—C6 | −0.9 (7) | N2—C7—C8—N3 | −155.9 (5) |
| C7—N2—C6—C5 | 178.8 (4) | N1—C7—C8—N3 | 29.6 (7) |
| C7—N2—C6—C1 | −0.7 (5) | C8—N3—C9—C10 | −162.1 (5) |
| C4—C5—C6—N2 | −177.7 (5) | C11B—N3—C9—C10 | 83.2 (9) |
| C4—C5—C6—C1 | 1.8 (7) | C11A—N3—C9—C10 | 56.2 (10) |
| N1—C1—C6—N2 | 0.4 (5) | C8—N3—C11A—C12A | −68.0 (13) |
| C2—C1—C6—N2 | 177.8 (4) | C9—N3—C11A—C12A | 73.8 (14) |
| N1—C1—C6—C5 | −179.2 (4) | C8—N3—C11B—C12B | 83.4 (15) |
| C2—C1—C6—C5 | −1.8 (7) | C9—N3—C11B—C12B | −162.5 (14) |
| C6—N2—C7—N1 | 0.8 (5) |
(1H-Benzodiazol-2-ylmethyl)diethylamine . Hydrogen-bond geometry (Å, º)
| D—H···A | D—H | H···A | D···A | D—H···A |
| N1—H1···N2i | 0.86 | 2.06 | 2.873 (4) | 157 |
Symmetry code: (i) −x+1/2, y, z+1/2.
References
- Agilent (2012). CrysAlis PRO. Agilent Technologies Ltd, Yarnton, England.
- Anzaldo-Olivares, B., Arroyo, M., Ramírez-Monroy, A. & Bernès, S. (2020). IUCrData, 5, x200281. [DOI] [PMC free article] [PubMed]
- Gaoxiang, M., Yang, Y., Li, Q. & Li, Z. (2022). Z. Krist. New Cryst. Struct.237, 191–193.
- Ghani, T. A. & Mansour, A. M. (2011). Spectrochim. Acta A Mol. Biomol. Spectrosc.81, 754–763. [DOI] [PubMed]
- Groom, C. R., Bruno, I. J., Lightfoot, M. P. & Ward, S. C. (2016). Acta Cryst. B72, 171–179. [DOI] [PMC free article] [PubMed]
- Krause, L., Herbst-Irmer, R., Sheldrick, G. M. & Stalke, D. (2015). J. Appl. Cryst.48, 3–10. [DOI] [PMC free article] [PubMed]
- Navarrete-Vázquez, G., Cedillo, R., Hernández-Campos, A., Yépez, L., Hernández-Luis, F., Valdez, J., Morales, R., Cortés, R., Hernández, M. & Castillo, R. (2001). Bioorg. Med. Chem. Lett.11, 187–190. [DOI] [PubMed]
- Parsons, S., Flack, H. D. & Wagner, T. (2013). Acta Cryst. B69, 249–259. [DOI] [PMC free article] [PubMed]
- Sheldrick, G. M. (2015a). Acta Cryst. A71, 3–8.
- Sheldrick, G. M. (2015b). Acta Cryst. C71, 3–8.
- Spek, A. L. (2020). Acta Cryst. E76, 1–11. [DOI] [PMC free article] [PubMed]
- Walia, R., Hedaitullah, M., Naaz, S. F., Iqbal, K. & Lamba, H. S. (2011). Int. J. Res. Pharm. & Chem.1, 565–574.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Crystal structure: contains datablock(s) global, I. DOI: 10.1107/S241431462401006X/hb4488sup1.cif
Structure factors: contains datablock(s) I. DOI: 10.1107/S241431462401006X/hb4488Isup2.hkl
Supporting information file. DOI: 10.1107/S241431462401006X/hb4488Isup3.cml
CCDC reference: 2376300
Additional supporting information: crystallographic information; 3D view; checkCIF report


